Burkitt Lymphoma
📧 Sign up to get email alerts when something new happens for Burkitt Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]
This document outlines a Phase 1/2 clinical trial (ViPOR) evaluating a combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and l…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes autologous stem cell transplant followed by polatuzumab vedotin for patients with various B-cell…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene [Phase 1, Phase 2]
An NCI-sponsored clinical trial is evaluating the safety of CX-5461 (Pidnarulex) in lymphomas with MYC alterations, including Burkitt lympho…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations [Phase 2]
Phase 2 study of CPI-613 (devimistat) for relapsed or refractory Burkitt lymphoma/leukemia and high-grade B-cell lymphoma with high-risk tra…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies [Phase 2]
Phase 2 clinical trial update describing a donor stem cell transplant conditioning regimen with treosulfan, fludarabine, and total-body irra…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma [Phase 1]
Phase 1 trial update of ViPOR-P (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in combination with polatuzumab for relapsed…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT [NA]
Clinical trial update indicates ongoing recruitment for a study evaluating CD45RA-depleted peripheral stem cell addback to prevent viral or …
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas [Phase 1]
Phase 1 trial evaluating pomalidomide with dose-adjusted EPOCH, with or without rituximab, for HIV-associated lymphomas; recruitment is ongo…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recr…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma [EARLY_Phase 1]
This clinical trial update reports an early-phase study of a novel Bispecific AbTCR (anti-CD19/CD22) T-cell therapy for relapsed or refracto…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update evaluating the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refrac…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL [Phase 2]
Phase 2 clinical trial evaluating obinutuzumab plus ICE chemotherapy for refractory or recurrent CD20-positive mature non-Hodgkin lymphoma i…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas [Phase 1]
Phase 1 clinical trial evaluating autologous CD22-directed CAR-T cells in patients with recurrent or refractory B-cell lymphomas, including …
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Allo HSCT Using RIC and PTCy for Hematological Diseases [Phase 2]
Phase 2 clinical trial evaluating allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and post-transplan…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Gut Health in Children With Cancer
A clinical trial update indicates that a study on gut health in children with cancer is currently recruiting, enrolling conditions including…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine [Phase 1]
A Phase 1 clinical trial evaluating a thiotepa, cyclophosphamide, clarithromycin, and cytarabine combination in adults with Burkitt lymphoma…
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Immunotherapy in Lymphoma
An ongoing immunotherapy trial for relapsed or refractory B-cell lymphomas is currently recruiting. The study targets high-grade B-cell lymp…